Literature DB >> 34152549

The inverse paradigm and the ancestral cell of IDH-wildtype glioblastoma.

Enrico Brognaro1.   

Abstract

Rethinking IDH-wildtype glioblastoma through its unique features can help researchers find innovative and effective treatments. It is currently emerging that, after decades of therapeutic impasse, some traditional concepts regarding IDH-wildtype glioblastoma need to be supplemented and updated to overcome therapeutic resistance. Indeed, multiple clinical aspects and recent indirect and direct experimental data are providing evidence that the supratentorial brain parenchyma becomes entirely and quiescently micro-infiltrated long before primary tumor bulk growth. Furthermore, they are indicating that the known micro-infiltration that occurs during the IDH-wildtype glioblastoma growth and evolution is not at the origin of distant relapses. It follows that the ubiquitous supratentorial brain parenchyma micro-infiltration as a source for the development of widespread distant recurrences is actually due to the silent stage that precedes tumor growth rather than to the latter. All this implies that, in addition to the heterogeneity of the primary bulk, there is a second crucial cause of therapeutic resistance that has never hitherto been identified and challenged. In this regard, the ancestral founder cancer stem cell (CSC) appears as the key cell that can link the two causes of resistance.
© 2021. Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Ancestral founder cancer stem cell; Inverse paradigm; Three steps to IDH-wildtype glioblastoma; Two causes of therapeutic resistance; Two widespread micro-infiltrations

Mesh:

Substances:

Year:  2021        PMID: 34152549     DOI: 10.1007/s12094-021-02663-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  31 in total

1.  Control of astrocyte migration in the developing cerebral cortex.

Authors:  Chad T Jacobsen; Robert H Miller
Journal:  Dev Neurosci       Date:  2003 Mar-Aug       Impact factor: 2.984

2.  Timing and patterns of astrocyte migration from xenogeneic transplants of the cortex and corpus callosum.

Authors:  H F Zhou; L H Lee; R D Lund
Journal:  J Comp Neurol       Date:  1990-02-08       Impact factor: 3.215

3.  Spatiotemporal Evolution of the Primary Glioblastoma Genome.

Authors:  Jinkuk Kim; In-Hee Lee; Hee Jin Cho; Chul-Kee Park; Yang-Soon Jung; Yanghee Kim; So Hee Nam; Byung Sup Kim; Mark D Johnson; Doo-Sik Kong; Ho Jun Seol; Jung-Il Lee; Kyeung Min Joo; Yeup Yoon; Woong-Yang Park; Jeongwu Lee; Peter J Park; Do-Hyun Nam
Journal:  Cancer Cell       Date:  2015-09-14       Impact factor: 31.743

4.  Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics.

Authors:  Andrea Sottoriva; Inmaculada Spiteri; Sara G M Piccirillo; Anestis Touloumis; V Peter Collins; John C Marioni; Christina Curtis; Colin Watts; Simon Tavaré
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-14       Impact factor: 11.205

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

Review 6.  A glial blueprint for gliomagenesis.

Authors:  Dylan Laug; Stacey M Glasgow; Benjamin Deneen
Journal:  Nat Rev Neurosci       Date:  2018-07       Impact factor: 34.870

Review 7.  Astrocytes and disease: a neurodevelopmental perspective.

Authors:  Anna V Molofsky; Robert Krencik; Robert Krenick; Erik M Ullian; Erik Ullian; Hui-hsin Tsai; Benjamin Deneen; William D Richardson; Ben A Barres; David H Rowitch
Journal:  Genes Dev       Date:  2012-05-01       Impact factor: 11.361

8.  Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.

Authors:  Inmaculada Spiteri; Andrea Sottoriva; Sara Gm Piccirillo; Anestis Touloumis; Suzan Ber; Stephen J Price; Richard Heywood; Nicola-Jane Francis; Karen D Howarth; Vincent P Collins; Ashok R Venkitaraman; Christina Curtis; John C Marioni; Simon Tavaré; Colin Watts
Journal:  Cancer Res       Date:  2014-11-18       Impact factor: 12.701

9.  Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.

Authors:  Hoon Kim; Siyuan Zheng; Seyed S Amini; Selene M Virk; Tom Mikkelsen; Daniel J Brat; Jonna Grimsby; Carrie Sougnez; Florian Muller; Jian Hu; Andrew E Sloan; Mark L Cohen; Erwin G Van Meir; Lisa Scarpace; Peter W Laird; John N Weinstein; Eric S Lander; Stacey Gabriel; Gad Getz; Matthew Meyerson; Lynda Chin; Jill S Barnholtz-Sloan; Roel G W Verhaak
Journal:  Genome Res       Date:  2015-02-03       Impact factor: 9.043

10.  Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.

Authors:  Khalil Abou-El-Ardat; Michael Seifert; Kerstin Becker; Sophie Eisenreich; Matthias Lehmann; Karl Hackmann; Andreas Rump; Gerrit Meijer; Beatriz Carvalho; Achim Temme; Gabriele Schackert; Evelin Schröck; Dietmar Krex; Barbara Klink
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.